Jasper Therapeutics Readies for Key Investor Conferences Soon
Jasper Therapeutics to Engage Investors at Major Conferences
Jasper Therapeutics, Inc. (NASDAQ: JSPR) has announced an exciting opportunity for investors and stakeholders as they prepare to participate in significant healthcare conferences. Focused on the promising development of briquilimab, a groundbreaking antibody therapy aimed at addressing mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma, Jasper is positioned as an innovative player in the biotechnology sector.
Upcoming Conferences
Jasper will showcase its advancements at two key investor events:
RBC Capital Markets 2025 Global Healthcare Conference
The RBC Capital Markets conference is scheduled for May 20-21, 2025. Jasper’s management will take the stage on May 21, 2025, at 11:00 a.m. EDT, presenting in a fireside chat format that promises to engage and inform attendees about the company’s developments and strategies moving forward.
Jefferies 2025 Global Healthcare Conference
The following month, Jasper will also be featured at the Jefferies 2025 Global Healthcare Conference from June 3-5, 2025. Their presentation is slated for June 5, 2025, at 11:40 a.m. EDT, where the team will outline their research and development, including insights into briquilimab.
Webcasts and Access
Investors and interested parties have the opportunity to engage with Jasper’s presentations through live webcasts available on the company’s Investor Relations website. Those who miss the live sessions need not worry; archived replays will be accessible for 30 days following each presentation, ensuring that all stakeholders stay informed.
About Briquilimab and Jasper Therapeutics
Jasper is dedicated to developing briquilimab as a targeted therapy for chronic mast cell diseases. This innovative treatment is an aglycosylated monoclonal antibody specifically designed to block stem cell factor from binding to cell-surface receptors known as KIT. The mechanism of action disrupts vital survival signals, leading to the depletion of mast cells through a process called apoptosis. This action potentially alleviates the inflammatory responses characteristic of CSU, CIndU, and asthma.
Current studies on briquilimab highlight its efficacy and safety profile, which has been validated through positive clinical outcomes in patients suffering from chronic urticaria and asthma. As Jasper continues its commitment to medical advancement, more updates are likely as they proceed with their clinical trials and engage with the medical community.
Contact Information
For investor inquiries, Alex Gray from Jasper Therapeutics can be reached at 650-549-1454 or via email at agray@jaspertherapeutics.com. Joyce Allaire from LifeSci Advisors is also available for investors at 617-435-6602, and can be contacted by email at jallaire@lifesciadvisors.com. For media inquiries, Lauren Walker from Real Chemistry can be contacted at 646-564-2156 or by email at lbarbiero@realchemistry.com.
Frequently Asked Questions
What is briquilimab?
Briquilimab is an innovative antibody therapy developed by Jasper Therapeutics to treat mast cell driven diseases, including chronic spontaneous urticaria and asthma.
When are Jasper's upcoming investor presentations?
Jasper will present at the RBC Capital Markets conference on May 21, 2025, and at the Jefferies conference on June 5, 2025.
How can the public access Jasper’s presentations?
Live webcasts of Jasper’s presentations will be available on their Investor Relations website, with archived replays accessible for 30 days post-presentation.
What specific diseases does briquilimab target?
Briquilimab targets diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma.
Who should I contact for more information about Jasper Therapeutics?
For inquiries, you can contact Alex Gray for investors, or reach out to Joyce Allaire for additional investor support, or Lauren Walker for media inquiries.
About The Author
Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
